Tonix Pharmaceuticals Announces Extension of Sponsored
TNX-2300, a Live Virus Vaccine Based on a Bovine Parainfluenza Virus Vector, in Development to Protect Against COVID-19 Co-Expression of the CD40-Ligand...
Source: globenewswire.com
Stay updated with breaking news from Ligand Will. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
TNX-2300, a Live Virus Vaccine Based on a Bovine Parainfluenza Virus Vector, in Development to Protect Against COVID-19 Co-Expression of the CD40-Ligand...